$0.04
-0.02 (-27.48%)
Open$0.05
Previous Close$0.06
Day High$0.07
Day Low$0.04
52W High$2.96
52W Low—
Volume—
Avg Volume968.4K
Market Cap1.60M
P/E Ratio—
EPS$-3.78
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+49,137.7% upside
Current
$0.04
$0.04
Target
$21.96
$21.96
$14.05
$21.96 avg
$26.87
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.88M | 1.58M | 5.52M |
| Net Income | -204,960,062 | -154,881,658 | -589,967 |
| Profit Margin | -10,887.4% | -10,343.0% | -10.7% |
| EBITDA | -147,089,407 | -117,325,723 | -924,468 |
| Free Cash Flow | — | — | -774,673 |
| Rev Growth | +19.1% | +19.1% | -1.7% |
| Debt/Equity | 1.21 | 1.21 | 0.23 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |